Introduction
Thrombotic thrombocytopenic pupura (TTP) is a lifethreatening disease characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and various organ dysfunctions such as neurological symptoms, renal damage, and fever. Idiopathic TTP is distinguished from secondary TTP following predisposing conditions like cancer, eclampsia, drug toxicity, or hematopoetic stem cell transplantation [1] . Acquired idiopathic TTP is differentiated from hereditary TTP (Upshaw-Schulman syndrome). Large progress was made in recent years in understanding the pathophysiology of TTP. Moake et al. [2] described unusually large von Willebrand factor (VWF) multimers in the plasma of patients with relapsing acquired or congenital TTP causing intravascular platelet aggregation occluding the microvasculature. Tsai [3] and Furlan et al. [4] independently identified a VWF-cleaving protease (ADAMTS13) missing from the plasma of patients with congenital TTP [5] and severely deficient in patients with acquired idiopathic TTP. Mutations in the ADAMTS13 gene were shown to cause congenital TTP [6] , whereas IgG autoantibodies inhibit the enzyme in most cases of the acquired form of the disease [7, 8] . The standard treatment of acquired idiopathic TTP consists of plasma exchange with fresh frozen plasma [9, 10] , thereby removing large VWF multimers as well as autoantibodies to ADAMTS13 and replacing the enzyme [11, 12] . As a result of this therapy, the overall survival could be improved from 10% to more than 80% [13, 14] . However, up to one third of patients relapse after successful treatment of an acute episode, and especially patients with initial severe ADAMTS13 deficiency have a significantly increased risk of relapsing TTP [11, 15] . In the case of plasma-refractory TTP, which is defined as persistent thrombocytopenia or lactate dehydrogenase elevation after a total of seven daily plasma exchange procedures, current guidelines advise to intensify plasma exchange and to add corticosteroids in patients not receiving immunosuppressive drugs [12] . Due to the autoimmune nature of acquired idiopathic TTP, rituximab has been used as a second-line immunosuppressive intervention in TTP cases refractory to plasma exchange as well as in frequently relapsing patients [16] [17] [18] [19] . According to treatment schedules in non-Hodgkin's lymphoma, rituximab is mainly administered at doses of 375 mg/m 2 weekly for an average of four doses. Using this regimen, although only a small number of patients have been reported worldwide, the majority of patients with refractory or relapsing TTP achieved complete remission with complete clinical and laboratory responses including normal ADAMTS13 level and disappearance of anti-ADAMTS13 antibodies [11] . In the reported cases, only 10-13% of patients relapsed after rituximab treatment after a median follow-up of 11 months [17, 18] . Especially when considering B cell recovery 9 to 12 months after rituximab application, data for long-term follow-up are required.
Therefore, we reevaluated all patients with non-familial idiopathic TTP refractory to plasma exchange or with recurrent disease treated with rituximab between 2000 and 2008 at the University Hospital of Cologne with a median follow-up of almost 50 months.
Design and methods
Diagnosis of TTP was based on clinical and laboratory findings-including consumptive thrombocytopenia, hemolytic anemia and elevated schistocytes in the peripheral blood smear-irrespective of ADAMTS13 activity. All patients were initially treated with standard treatment including daily plasma exchange with fresh frozen plasma (1.5× plasma volume) and corticosteroids. Decision of rituximab treatment initiation was made in case of nonresponse to daily plasma exchange, severe allergic reactions to plasma exchange leading to treatment discontinuation or relapse after initial successful therapy. During 2000 and 2008, 30 patients with an acute episode of non-familial idiopathic TTP were treated at the University Hospital of Cologne; 12 patients treated with rituximab were identified and reexamined. Due to different pathophysiology, patients with TTP secondary to bone marrow transplantation, rheumatologic diseases, or active cancer were excluded.
In most cases, treatment schedule consisted of rituximab at a dose of 375 mg/m 2 per week for four consecutive weeks administered in parallel to daily plasma exchange, except for two patients with intolerance to plasma exchange after a total of 22 and 10 exchange procedures leading to disruption of plasma exchange therapy. After application of rituximab, plasma exchange was interrupted for 24 h. In general, plasma exchange was continued until clinical remission and platelet count above 150×10 9 /l for longer than 48 h.
Non-response to plasma exchange was defined as either persistent thrombocytopenia or elevated lactate dehydrogenase (LDH) after 1 week of ongoing daily plasma exchange with fresh frozen plasma. Relapse was defined as recurrence of at least one further acute TTP episode after initial successful standard therapy with plasma exchange. Complete response was defined as a sustained normal platelet count, absence of clinical symptoms of TTP, and cessation of plasma exchange therapy.
At the end of follow-up, documentation of clinical symptoms including any possible side effects related to rituximab therapy was performed after all patients gave their informed consent. In addition to complete medical history, physical examination, and standard laboratory testing, ADAMTS13 enzyme activity and the presence of an inhibitor were analyzed. ADAMTS13 activity was analyzed using the TECHNOZYM ADAMTS13 activity ELISA according to manufacturer's instructions. The presence of an inhibitor was analyzed using TECHNOZYM ADAMTS13 INH ELISA (both Technoclone Deutschland, Heidelberg, Germany). To evaluate the degree of present B cell depletion at the end of follow-up, CD19 measurement was performed using flow cytometry. Prior to the collection of data, the study was examined by the local ethics committee.
Results and discussion
At the time of initial TTP diagnosis, median age of the 12 patients was 42.5 years. Seventy-five percent of patients were female. The main clinical manifestations during acute TTP episode consisted of neurological symptoms (n=7), renal impairment (n=2), or abdominal pain (n=4). At presentation, the mean platelet count was decreased to 19.8×10 9 /l, and mean LDH was elevated to 1,018 U/l (reference <250 U/l). All patients had plasma exchange with fresh frozen plasma and steroid treatment prior to rituximab. Four patients were additionally treated with vincristine (2 mg, i.v.). Seven patients were treated during the first episode of acute TTP; among those, five received rituximab because of insufficient standard therapy with plasma exchange. Two patients suffered from severe allergic reaction leading to disruption of plasma exchange after 22 and 10 exchange procedures. Five patients received rituximab because of relapse after at least one prior episode of acute TTP initially successfully treated with standard therapy. Baseline characteristics of all patients are shown in Table 1 . Due to assay availability, unfortunately, only in a minority of patients was ADAMTS13 activity analyzed before initiation of rituximab therapy. After application of rituximab, no severe acute side effects were noted and all patients responded with complete remission. This is in line with previous data reporting acute response rates of more than 90% [11, 20] .
After nearly 50 months of follow-up, 3 of 12 patients had relapsed. Previous reports estimate the relapse rate after rituximab at approx. 10% [11, 17, 18] . However, these existing data are based on few patients with short follow-up; thus, objective statements to frequency of relapse after rituximab cannot be made to this time point. The higher relapse rate in our collective is probably reflecting the longer follow-up period reported in the present study with transient B cell depletion and subsequent formation of new antibodies directed against ADAMTS13. Notably, five patients suffered from partly frequent relapses before initiation of rituximab treatment. Three of these patients remained disease-free even after long-term follow-up. Only one patient relapsed after rituximab treatment during the initial TTP episode. All relapsing patients responded to subsequent rituximab therapy. Interestingly, the two patients treated with rituximab during initial TTP episode due to severe allergic reaction after initial standard therapy with plasma exchange had a sustained response without recurrence of TTP after a follow-up of 36 and 40 months. The individual participation of plasma exchange or rituximab to successful treatment remains open; however, both patients did not achieve complete remission after cessation of plasma exchange. In two patients, a maintenance therapy with rituximab was initiated consisting of 375 mg/m 2 every 4 weeks. One patient remains diseasefree with ongoing maintenance therapy; the other is in sustained complete remission despite abortion of maintenance therapy after 3 months.
Treatment decision making in the case of further relapse after rituximab is difficult and not evidence based to this time point. Rituximab has been used as preemptive treatment in patients with anti-ADAMTS13 autoantibodies [21] ; thus, rituximab maintenance maybe an option, however possibly related to long-term side effects like progressive multifocal leukoencephalopathy [22] . An alternative treatment option would be a splenectomy, which is supported by data provided by Kappers-Klunne et al. [23] . Thirty-three patients with TTP were retrospectively reported who were splectomized due to refractory or relapsing disease. After median follow-up of 109 months, the 10-year relapse-free survival was 70%. As these data were generated without rituximab being a treatment alternative, one has to balance between risks of the operation procedure, postoperative complications, as well as infectious complications post-splenectomy against consequences of long-term B cell depletion during rituximab maintenance therapy. This patient had been formally reported [16] In our patient collective, no patient suffered from consequences of long-term B cell depletion since no treatment-related, especially infectious, complications were reported. In all but two patients, B cell counts had recovered at the end of follow-up; one of the two patients is currently treated with rituximab maintenance therapy. Thus, the safety profile of rituximab used in this hematological autoimmune disorder seems to be justifiable; however, the number of patients presented here is too small to conclude rituximab as being a safe treatment option in refractory or relapsing TTP.
At the end of follow-up, ADAMTS13 activity and the presence of an inhibitor were analyzed. Testing ADAMTS13 activity during remission is recommended since idiopathic TTP caused by ADAMTS13 deficiency relapses more frequently, and monitoring might identify patients presenting without TTP-related symptoms, however with imminent relapse [11] . In our patient collective, ADAMTS13 activity was reduced in 25%. No patient had an enzyme activity <5%, which would imply the need of subsequent rituximab therapy, although patient 12 presenting with ADAMTS13 activity of 7% and high inhibitor concentrations (64 U/ml) is closely monitored. Inhibitors against ADAMTS13 at time of reevaluation were detected in four patients.
The favor of the reported data is a long follow-up. A median follow-up of nearly 50 months is reflecting the longest follow-up period after rituximab treatment reported to date. In the existing literature, patients treated with plasma exchange and rituximab have been followed for up to 3 years [17, 18] ; however, median follow-up is reported to be <11 months [12] . Longer follow-up is required for addressing possible long-term side effects of rituximab and the safety of this treatment procedure [24] . Moreover, reflecting the initial high response rates after rituximab treatment, longer follow-up periods are required to assess the exact benefit of this therapy, since late relapses have to be taken into account. The limitation of the present study is the retrospective design possibly leading to incomplete reporting of adverse events during the long follow-up period. However, most patients were seen on a regular basis in our outpatient clinic, and medical history as well as laboratory testing was routinely performed. Another limitation is the small patient number, making it difficult to draw final conclusions especially regarding the safety of rituximab treatment in TTP. These limitations in mind, it appears that rituximab is an effective second-line treatment option for patients with idiopathic TTP, with some patients achieving sustained responses even after long-term follow-up. Prospective multicenter studies are needed to determine whether rituximab can be safely used just as salvage therapy or even initially in addition to plasma exchange to decrease the relapse rate after first-line treatment [25] .
